

# Davide Campana

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4605317/davide-campana-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

3,011  
citations

30  
h-index

52  
g-index

137  
ext. papers

3,498  
ext. citations

3.9  
avg, IF

4.64  
L-index

#	Paper	IF	Citations
122	Role of [F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors.. <i>Endocrine</i> , <b>2022</b> , 1	4	1
121	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e220290 <sup>10.4</sup>	0	0
120	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	4
119	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4167-TPS4167	2.2	
118	Adjuvant chemotherapy in nonmetastatic goblet cell carcinomas: A population-based analysis.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16203-e16203	2.2	
117	Large cell neuroendocrine carcinoma of the lung: Prognostic factors to predict clinical outcomes.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e20515-e20515	2.2	
116	A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
115	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , <b>2021</b> , 9, 423-438	2	1
114	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. <i>Endocrine</i> , <b>2021</b> , 72, 268-278	4	4
113	Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis. <i>Updates in Surgery</i> , <b>2021</b> , 1	2.9	
112	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
111	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
110	The 3-Dimensional-Computed Tomography Texture Is Useful to Predict Pancreatic Neuroendocrine Tumor Grading.. <i>Pancreas</i> , <b>2021</b> , 50, 1392-1399	2.6	1
109	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1
108	Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 122, 570-571	2.8	2
107	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , <b>2020</b> , 25, 259-265	5.7	9
106	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2020</b> , 182, 439-446	6.5	11

105	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , <b>2020</b> , 27, 275-283	5.7	3
104	Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. <i>Anti-Cancer Drugs</i> , <b>2020</b> , 31, 1103-1105	2.4	2
103	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , <b>2020</b> , 35, 141-148	2.5	6
102	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
101	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , <b>2020</b> , 271, 527-533	7.8	27
100	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	14
99	The functioning side of the pancreas: a review on insulinomas. <i>Journal of Endocrinological Investigation</i> , <b>2020</b> , 43, 139-148	5.2	13
98	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	18
97	Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management. <i>Surgery</i> , <b>2019</b> , 166, 952	3.6	
96	Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis. <i>Endocrine</i> , <b>2019</b> , 66, 460-466	4	7
95	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1456-1460	3.3	18
94	Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience. <i>Endocrine</i> , <b>2019</b> , 65, 207-212	4	5
93	Comment on "Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors": A National Study From the French Group of Endocrine Tumors (GTE). <i>Annals of Surgery</i> , <b>2019</b> , 270, e43-e44	7.8	3
92	Cutaneous Scapular Lesion in an Elderly Woman. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1355-1356	13.4	1
91	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , <b>2019</b> , 19, 1067-1073	3.8	7
90	A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience. <i>Endocrine</i> , <b>2019</b> , 64, 702-707	4	
89	Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes. <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, e0784	2.4	3
88	68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , <b>2019</b> , 44, 238-239	1.7	2

87	Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct. <i>ACG Case Reports Journal</i> , <b>2019</b> , 6, e00104	0.6	
86	Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 689-694	3.3	18
85	Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. <i>Pancreatology</i> , <b>2018</b> , 18, 313-317	3.8	10
84	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , <b>2018</b> , 18, 198-203	3.8	14
83	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum <b>2018</b> , 219-234		
82	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , <b>2018</b> , 155, 479-489.e7	13.3	36
81	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 607-618	5.7	13
80	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. <i>Journal of Chemotherapy</i> , <b>2018</b> , 30, 53-58	2.3	3
79	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3200-3206	3.1	23
78	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	30
77	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). <i>Annals of Oncology</i> , <b>2018</b> , 29, viii467-viii468	10.3	44
76	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , <b>2018</b> , 60, 490-498	4	41
75	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. <i>International Journal of Endocrinology</i> , <b>2018</b> , 2018, 8126087	2.7	40
74	Prognostic factors in ectopic Cushing $\beta$ syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 453-461	6.5	39
73	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , <b>2017</b> , 46, 302-305	2.6	37
72	Is surgery the best treatment for sporadic small ( $\leq 2$ cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. <i>Pancreatology</i> , <b>2017</b> , 17, 471-477	3.8	15
71	Sporadic Small ( $\leq 20$ mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2603-2610	3.1	24
70	I marcatori neuroendocrini nella pratica clinica: utilit�e limiti. <i>L Endocrinologo</i> , <b>2017</b> , 18, 64-65	0	

69	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , <b>2017</b> , 56, 633-638	4	25
68	Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. <i>Gastroenterology Research and Practice</i> , <b>2017</b> , 2017, 7872519	5.6	7
67	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , <b>2016</b> , 51, 131-9	4	31
66	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , <b>2016</b> , 103, 531-7	5.6	18
65	Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. <i>Pancreatology</i> , <b>2016</b> , 16, 403-10	3.8	23
64	<sup>68</sup> Ga DOTANOC PET/CT detects primary malignant insulinoma. <i>Clinical Nuclear Medicine</i> , <b>2015</b> , 40, e132-37	3.7	9
63	Prognostic Value of <sup>68</sup> Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1843-8	8.9	58
62	Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms. <i>Neuroendocrinology</i> , <b>2015</b> , 101, 25-34	5.6	8
61	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , <b>2014</b> , 19, 966-74	5.7	66
60	WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old?. <i>Pancreatology</i> , <b>2014</b> , 14, 539-41	3.8	14
59	Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. <i>Pancreas</i> , <b>2014</b> , 43, 212-8	2.6	38
58	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 176-7	8.8	
57	Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. <i>Endocrine</i> , <b>2013</b> , 44, 815-6	4	1
56	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1197-205	8.8	44
55	The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. <i>Pancreatology</i> , <b>2013</b> , 13, 589-93	3.8	23
54	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. <i>Hpb</i> , <b>2013</b> , 15, 935-43	3.8	11
53	Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. <i>Clinical Investigation</i> , <b>2012</b> , 2, 1123-1131		
52	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. <i>Neuroendocrinology</i> , <b>2012</b> , 96, 32-40	5.6	44

51	An acute and severe immunodeficiency syndrome due to a pancreatic ACTH-producing tumor. <i>Emergency Care Journal</i> , <b>2012</b> , 8, 19	1.2	1
50	<sup>68</sup> Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39 Suppl 1, S52-60	8.8	93
49	Is <sup>68</sup> Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1278-83	8.8	31
48	Factors related to long-term survival in patients affected by well-differentiated endocrine tumors of the pancreas. <i>ISRN Surgery</i> , <b>2012</b> , 2012, 389385		6
47	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 817-23	5.2	48
46	New WHO classification for pancreatic endocrine tumors: Is time to leave the previous one?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14647-e14647	2.2	
45	Metastatic 5-mm rectal neuroendocrine carcinoma. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, e25	3.3	
44	PET/CT with <sup>68</sup> Gallium-DOTA-peptides in NET: an overview. <i>European Journal of Radiology</i> , <b>2011</b> , 80, e116-9	4.7	32
43	When should F-18 FDG PET/CT be used instead of <sup>68</sup> Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors?. <i>Clinical Nuclear Medicine</i> , <b>2011</b> , 36, 1109-11	1.7	4
42	<sup>68</sup> Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. <i>Clinical Nuclear Medicine</i> , <b>2011</b> , 36, 64-5	1.7	18
41	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2372-7	2.2	216
40	Standardized uptake values of ( <sup>68</sup> )Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 353-9	8.9	133
39	Are there prognostic factors related to recurrence in pancreatic endocrine tumors?. <i>Pancreatology</i> , <b>2010</b> , 10, 33-8	3.8	33
38	<sup>68</sup> Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 669-73	8.9	197
37	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 457-8	3.3	5
36	Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 93-9	2.4	29
35	Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. <i>Pancreas</i> , <b>2010</b> , 39, 825-8	2.6	56
34	( <sup>68</sup> )Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 722-7	8.8	83

33	Warm water and oil assistance in colonoscopy. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 3286-7; author reply 3287-8	4	1
32	Patient-reported outcomes in patients with endocrine tumors of the ileum. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 689-94	2.2	2
31	Maffucci Syndrome with Hemangioma of the Liver. <i>Case Reports in Gastroenterology</i> , <b>2009</b> , 3, 1-4	1	6
30	Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. <i>World Journal of Surgery</i> , <b>2009</b> , 33, 2458-63	3.3	18
29	Warm water and oil for the difficult colon. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 69, 391; author reply 392	5.2	
28	Water-related techniques in colonoscopy: the end justifies the means!. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 70, 1287-9; author reply 1289	5.2	1
27	Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: a prospective study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 888-93	2.4	22
26	Evaluation of patient-reported outcome in subjects treated medically for acute pancreatitis: a follow-up study. <i>Pancreatology</i> , <b>2009</b> , 9, 375-82	3.8	12
25	Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 5067-73	5.6	28
24	Multiple gastric endocrine tumours and gastrinomas of the duodenum in a patient with ZES MEN 1. <i>Digestive and Liver Disease</i> , <b>2008</b> , 40, 476	3.3	1
23	Sedation on demand and lubrication during colonoscopy: should we change our minds?. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 68, 1028-9; author reply 1029	5.2	1
22	Warm water or oil-assisted colonoscopy: toward simpler examinations?. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 581-7	0.7	70
21	Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. <i>Endocrine-Related Cancer</i> , <b>2008</b> , 15, 337-42	5.7	54
20	Sedation during colonoscopy and the benefits of lubrication. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 207-8; author reply 208-9	6.1	1
19	Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35, 1431-8	8.8	220
18	Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39, 1077-86	3.3	50
17	Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. <i>Clinical Endocrinology</i> , <b>2007</b> , 67, 761-6	3.4	22
16	Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. <i>Journal of Gastroenterology</i> , <b>2007</b> , 42, 754-60	6.9	18



15	Chromogranin A: is it a useful marker of neuroendocrine tumors?. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1967-73	2.2	183
14	Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , <b>2007</b> , 28, 473-7	1.6	43
13	Endocrine tumors of the ileum: factors correlated with survival. <i>Neuroendocrinology</i> , <b>2006</b> , 83, 380-6	5.6	39
12	Medical treatment of endocrine gastroenteropancreatic tumors. <i>JOP: Journal of the Pancreas</i> , <b>2006</b> , 7, 145-9	1.2	1
11	Lubrication during colonoscopy: a forgotten factor. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 630-1	3.3	4
10	The ELISA fecal elastase-1 polyclonal assay reacts with different antigens than those of the monoclonal assay. <i>Pancreas</i> , <b>2005</b> , 31, 200-1	2.6	10
9	Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2005</b> , 17, 1413-5	2.2	19
8	Endocrine pancreatic tumors: factors correlated with survival. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1806-10	10.3	154
7	Treatment of Zollinger-Ellison syndrome. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 5423-32	5.6	16
6	Pancreatic involvement in systemic sarcoidosis. A case report. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 222-3	3.3	10
5	Basis for treatment of functioning neuroendocrine tumours. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36 Suppl 1, S35-41	3.3	2
4	Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients. <i>Drugs and Aging</i> , <b>2003</b> , 20, 1019-34	4.7	3
3	Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. <i>Anticancer Research</i> , <b>2003</b> , 23, 2969-72	2.3	5
2	A meal stimulation test in the diagnosis of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. <i>Endocrine</i> , <b>2002</b> , 17, 229-32		3
1	Effect of intravenous infusion of amino acids on pancreatic secretion. <i>Hepato-Gastroenterology</i> , <b>2002</b> , 49, 822-4		